Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H19NO2 |
Molecular Weight | 245.3169 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)NC[C@@H]1C[C@H]1C2=CC=CC3=C2CCO3
InChI
InChIKey=PTOIAAWZLUQTIO-GXFFZTMASA-N
InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
Molecular Formula | C15H19NO2 |
Molecular Weight | 245.3169 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/?term=19579175
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/?term=19579175
Tasimelteon, developed by Vanda Pharmaceuticals Inc under license from Bristol-Myers Squibb Co, is a melatonin receptor agonist. Tasimelteon differs structurally from melatonin and drugs with known melatonin agonist activity, in particular by its distinct aromatic group and linker. Tasimelteon bears also no structural relationship to any other approved active substance. Tasimelteon is presumably acts through activation of MT1 and MT2 G-protein coupled receptors, which are involved primarily in inhibition of neuronal firing and phase shift of circadian rhythms. Tasimelteon is approved for the treatment of Non24-Hour Sleep-Wake Disorder.
Originator
Sources: https://newdrugapprovals.org/tag/tasimelteon/
Curator's Comment: In May 2013 Vanda Pharmaceuticals submitted a New Drug Application to the Food and Drug Administration for Tasimelteon
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P49286 Gene ID: 4544.0 Gene Symbol: MTNR1B Target Organism: Homo sapiens (Human) |
0.0692 nM [Ki] | ||
Target ID: P48039 Gene ID: 4543.0 Gene Symbol: MTNR1A Target Organism: Homo sapiens (Human) |
0.304 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | HETLIOZ Approved UseIndicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). Launch Date2014 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
445 ng/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
786 ng/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5 ng/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
33 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
173 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
394 ng/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
12 ng/mL |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
51 ng/mL |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
261 ng/mL |
50 mg 1 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
873 ng/mL |
150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2304 ng × h/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
2269 ng × h/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8 ng × h/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
59 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
426 ng × h/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1823 ng × h/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
17 ng × h/mL |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
96 ng × h/mL |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
611 ng × h/mL |
50 mg 1 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3797 ng × h/mL |
150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.06 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
2.75 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.75 h |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.29 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.37 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.78 h |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.49 h |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.44 h |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.57 h |
50 mg 1 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.63 h |
150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASIMELTEON plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disc. AE: Supraventricular extrasystoles, Vomiting... AEs leading to discontinuation/dose reduction: Supraventricular extrasystoles (0.7%) Sources: Vomiting (0.7%) Headache (0.7%) Syncope (0.7%) Insomnia (0.7%) Nightmare (1.3%) Anger (0.7%) Depression (0.7%) |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disc. AE: Supraventricular extrasystoles, Tachycardia... AEs leading to discontinuation/dose reduction: Supraventricular extrasystoles (0.07%) Sources: Tachycardia (0.07%) Constipation (0.07%) Fatigue (0.07%) Oedema peripheral (0.07%) Cholestasis (0.07%) ALT increased (0.07%) AST increased (0.07%) GGT increased (0.07%) Blood creatine increased (0.07%) Hyperglycaemia (0.07%) Headache (0.07%) Loss of consciousness (0.07%) Syncope (0.07%) Transient ischaemic attack (0.07%) Insomnia (0.14%) Nightmare (0.14%) Renal pain (0.07%) Rash (0.07%) |
1 mg 1 times / day multiple, oral Studied dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disc. AE: Local swelling, Disorientation... AEs leading to discontinuation/dose reduction: Local swelling (0.07%) Sources: Disorientation (0.07%) Rash (0.07%) |
10 mg 1 times / day multiple, oral Studied dose Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disc. AE: Diarrhoea, Gastritis... AEs leading to discontinuation/dose reduction: Diarrhoea (0.07%) Sources: Gastritis (0.07%) Dizziness (0.07%) |
100 mg 1 times / day multiple, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (0.07%) Sources: |
150 mg 1 times / day multiple, oral Studied dose Dose: 150 mg, 1 times / day Route: oral Route: multiple Dose: 150 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (0.07%) Sources: |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disc. AE: Ventricular arrhythmia, Gastritis... AEs leading to discontinuation/dose reduction: Ventricular arrhythmia (0.9%) Sources: Gastritis (0.9%) Local swelling (0.9%) Electrocardiogram ST segment elevation (0.9%) Ataxia (0.9%) Dizziness (0.9%) Confusional state (0.9%) Disorientation (0.9%) Rash (0.9%) |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disc. AE: Supraventricular extrasystoles, Ventricular arrhythmia... AEs leading to discontinuation/dose reduction: Supraventricular extrasystoles (0.2%) Sources: Ventricular arrhythmia (0.2%) Diarrhoea (0.2%) Dyspepsia (0.2%) Gastritis (0.2%) Hypoaesthesia oral (0.2%) Vomiting (0.2%) Local swelling (0.2%) Somnolence (0.5%) Ataxia (0.2%) Dizziness (0.2%) Headache (0.2%) Syncope (0.2%) Insomnia (0.5%) Nightmare (0.5%) Anger (0.2%) Confusional state (0.2%) Depression (0.2%) Disorientation (0.2%) Rash (0.2%) |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disc. AE: Diarrhoea, Dyspepsia... AEs leading to discontinuation/dose reduction: Diarrhoea (0.6%) Sources: Dyspepsia (0.6%) Hypoaesthesia oral (0.6%) Blood creatine phosphokinase increased (0.6%) Somnolence (1.2%) Insomnia (0.6%) |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disc. AE: Dyspepsia, Blood creatine increased... AEs leading to discontinuation/dose reduction: Dyspepsia (0.07%) Sources: Blood creatine increased (0.07%) Somnolence (0.07%) Insomnia (0.07%) |
300 mg 1 times / day multiple, oral Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
healthy, 18-44 years Health Status: healthy Age Group: 18-44 years Sex: M+F Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anger | 0.7% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Depression | 0.7% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Headache | 0.7% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Insomnia | 0.7% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Supraventricular extrasystoles | 0.7% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Syncope | 0.7% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Vomiting | 0.7% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Nightmare | 1.3% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
ALT increased | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
AST increased | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Blood creatine increased | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Cholestasis | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Constipation | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Fatigue | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
GGT increased | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Headache | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Hyperglycaemia | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Loss of consciousness | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Oedema peripheral | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Rash | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Renal pain | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Supraventricular extrasystoles | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Syncope | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Tachycardia | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Transient ischaemic attack | 0.07% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Insomnia | 0.14% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Nightmare | 0.14% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disorientation | 0.07% Disc. AE |
1 mg 1 times / day multiple, oral Studied dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Local swelling | 0.07% Disc. AE |
1 mg 1 times / day multiple, oral Studied dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Rash | 0.07% Disc. AE |
1 mg 1 times / day multiple, oral Studied dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Diarrhoea | 0.07% Disc. AE |
10 mg 1 times / day multiple, oral Studied dose Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Dizziness | 0.07% Disc. AE |
10 mg 1 times / day multiple, oral Studied dose Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Gastritis | 0.07% Disc. AE |
10 mg 1 times / day multiple, oral Studied dose Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Vomiting | 0.07% Disc. AE |
100 mg 1 times / day multiple, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Rash | 0.07% Disc. AE |
150 mg 1 times / day multiple, oral Studied dose Dose: 150 mg, 1 times / day Route: oral Route: multiple Dose: 150 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Ataxia | 0.9% Disc. AE |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Confusional state | 0.9% Disc. AE |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disorientation | 0.9% Disc. AE |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Dizziness | 0.9% Disc. AE |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Electrocardiogram ST segment elevation | 0.9% Disc. AE |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Gastritis | 0.9% Disc. AE |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Local swelling | 0.9% Disc. AE |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Rash | 0.9% Disc. AE |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Ventricular arrhythmia | 0.9% Disc. AE |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Anger | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Ataxia | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Confusional state | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Depression | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Diarrhoea | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Disorientation | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Dizziness | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Dyspepsia | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Gastritis | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Headache | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Hypoaesthesia oral | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Local swelling | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Rash | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Supraventricular extrasystoles | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Syncope | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Ventricular arrhythmia | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Vomiting | 0.2% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Insomnia | 0.5% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Nightmare | 0.5% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Somnolence | 0.5% Disc. AE |
25 mg 1 times / day multiple, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Blood creatine phosphokinase increased | 0.6% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Diarrhoea | 0.6% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Dyspepsia | 0.6% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Hypoaesthesia oral | 0.6% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Insomnia | 0.6% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Somnolence | 1.2% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Blood creatine increased | 0.07% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Dyspepsia | 0.07% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Insomnia | 0.07% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Somnolence | 0.07% Disc. AE |
50 mg 1 times / day multiple, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 18 - 92 years Health Status: unhealthy Age Group: 18 - 92 years Sex: M+F Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf#page=8 Page: 8.0 |
no | |||
no | ||||
no | ||||
no | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf#page=8 Page: 8.0 |
no | |||
no | ||||
no | ||||
no | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf#page=8 Page: 8.0 |
no | |||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf#page=8 Page: 8.0 |
no | |||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf#page=8 Page: 8.0 |
yes | yes (co-administration study) Comment: Rifampin, a strong CYP3A4 and moderate CYP2C8, CYP2C9/2C19 inducer, decreased the exposure of tasimelteon by approximately 90%. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf#page=8 Page: 8.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf#page=8 Page: 8.0 |
yes | yes (co-administration study) Comment: Rifampin, a strong CYP3A4 and moderate CYP2C8, CYP2C9/2C19 inducer, decreased the exposure of tasimelteon by approximately 90%. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf#page=8 Page: 8.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | yes (co-administration study) Comment: Drug interaction studies with CY1A2 inhibitor, fluvoxamine and CYP3A4 inducer, rifampin resulted in 6.5 fold increase and 90% decrease in tasimelteon exposure respectively. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf#page=5 Page: 5.0 |
|||
major | yes (co-administration study) Comment: Drug interaction studies with CY1A2 inhibitor, fluvoxamine and CYP3A4 inducer, rifampin resulted in 6.5 fold increase and 90% decrease in tasimelteon exposure respectively. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf#page=5 Page: 5.0 |
|||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000PharmR.pdf#page=28 Page: 28.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Analysis of low level radioactive metabolites in biological fluids using high-performance liquid chromatography with microplate scintillation counting: method validation and application. | 2005 Sep 1 |
|
Melatonin and its agonists: an update. | 2008 Oct |
|
New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. | 2009 |
|
Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. | 2009 Feb 7 |
|
Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. | 2009 Jul |
|
Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat. | 2009 Jun 26 |
|
Melatonin agonists and insomnia. | 2010 Feb |
|
Gateways to clinical trials. | 2010 Jan-Feb |
|
Investigational melatonin receptor agonists. | 2010 Jun |
|
Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. | 2010 Nov |
|
A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. | 2010 Sep |
|
[The newer sedative-hypnotics]. | 2010 Sep |
|
Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients. | 2014 Dec |
|
Tasimelteon: a selective and unique receptor binding profile. | 2015 Apr |
|
Tasimelteon for the treatment of non-24-hour sleep-wake disorder. | 2015 Jan |
Patents
Sample Use Guides
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:14:55 GMT 2025
by
admin
on
Mon Mar 31 18:14:55 GMT 2025
|
Record UNII |
SHS4PU80D9
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N05CH03
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
||
|
NDF-RT |
N0000175743
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
||
|
FDA ORPHAN DRUG |
297409
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/10/841
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
HETLIOZ (AUTHORIZED: SLEEP DISORDERS, CICARDIAN RHYTHM)
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
||
|
NCI_THESAURUS |
C47795
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
||
|
FDA ORPHAN DRUG |
301410
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SS-70
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
SHS4PU80D9
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
SHS4PU80D9
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
10220503
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
609799-22-6
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
7393
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
DTXSID70209826
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
79042
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
1490468
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | RxNorm | ||
|
C152515
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
100000157714
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
4820
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
m10478
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
8985
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
SUB166225
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103822
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
DB09071
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
TASIMELTEON
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY | |||
|
C478745
Created by
admin on Mon Mar 31 18:14:55 GMT 2025 , Edited by admin on Mon Mar 31 18:14:55 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
TARGET -> AGONIST | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
TARGET -> AGONIST | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
SINGLE- OR MULTIPLE-DOSE ADMINISTRATION |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||